UA122144U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis involves conducting a clinical examination, study of low and high density lipoprotein cholesterol levels, arteriography. In the serum determine the polymorphism of the genes MTHFR C677T, eNOS T786C, the content of thrombomodulin, cobalamin, IL-6, PSA, TGF- (1. When homozygous carrier 677-TT, 786-SS, levels of thrombomodulin 300 <5ba, 5 lb> 5 lb> 5 l ng / ml, IL-6> 10 ng / l, SRP> 6 mg / l, TGF- (1 <14 ng / ml diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography (A.N. Okorokov. Diagnostics of diseases of internal organs. -Vol. 6-S. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, along with the study of low- and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the genes methylenetetrahydrofolate reductase (MITNEV Сб677Т), nitric oxide synthase (emo5 T786С), the content of thrombomodulin, cobalamin, interleukin 6 (IL-6 ), C-reactive protein (SRP), transforming growth factor beta 1 (TGF-B1). With homozygous carrier 67 7-17, 786-SS, levels of thrombomodulin "5 ng/ml, cobalamin "300 ng/ml, IL-6 "10 ng/l, SRP "b6 mg/l,

TFR-B1-14 ng/ml diagnose the development of atherosclerosis.

Application of the method.

During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. Gene polymorphisms are determined in blood serum

MTNEV C677tT, emMmO5 1T786С, immunoenzymatic method - the content of thrombomodulin, cobalamin,

IL-6, SRP, TFR-DVI1. With homozygous carrier 677-HT, 786-SS, levels of thrombomodulin 25 ng/ml, cobalamin "300 ng/ml, IL-b" 10 ng/l, SRP "b mg/l, TFR-VD1" 14 ng/ml are diagnosed development of atherosclerosis.

A specific example of using the method.

Patient K., 46 years old, was hospitalized in the clinic with a diagnosis of rheumatoid arthritis. Examined

Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. There are no signs of atherosclerosis. Polymorphism of MTNEV genes was determined in blood serum

From Сб7/7и and емМмОо5 Т786О0. The content of thrombomodulin, cobalamin, IL-6, SRP, TGF-B1 was determined by immunoenzymatic method. Homozygous carriers of 677-TT and 786-SS were established. Levels of thrombomodulin - 9.8 ng/ml, cobalamin - 215 ng/ml, IL-6-16 ng/l, SRP - 10.8 mg/l, TGF-B1-7.8 ng/ml. The development of atherosclerosis was diagnosed. Arteriographic signs of the latter were detected only after 9 months.

Thus, the proposed method allows diagnosing atherosclerosis in the early stages.

Claims (1)

USEFUL MODEL FORMULA 40 The method of diagnosing the development of atherosclerosis, which includes conducting a clinical examination, researching low and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by the fact that the polymorphism of the MTNEV C677tT, emo5 T786C genes, the content of thrombomodulin, cobalamin, IL-6, SRP are determined in the blood serum , TFR-RI, and with homozygous carrier 677-TT, 786-SS, levels of thrombomodulin "5 ng/ml, cobalamin "300 ng/ml, IL-6 "10 ng/l, SRP "b mg/l, 45 TFR-DI1 "14 ng/ml diagnoses the development of atherosclerosis.